News
Video
Author(s):
Dr. Bruna Pellini presents key data comparing real-world outcomes of atezolizumab versus durvalumab in extensive-stage small cell lung cancer (ES-SCLC), demonstrating a significant overall survival advantage and lower immune-related adverse events with durvalumab, while progression-free survival remained comparable between the two treatments.
CORRECTION: Atezolizumab has an Overall Survival (OS) of 11.6 months, not 18.6.